Marco Moschini
Marco Moschini is an expert in Urology at IRCCS Ospedale San Raffaele (Italy). As of October 2026, ScienceLeadR ranks Marco Moschini in the top 1% of experts worldwide for Urinary Bladder Diseases, Urologic Neoplasms and Urogenital Neoplasms. Marco Moschini has authored 1,049 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 5 of them ongoing. SLR score: 3,245 (community average: 125). How the SLR is computed.
LeadR Profile
Urology
Subspecialties: Oncology - Surgery - Nephrology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2011 - 2026
Number : 1049
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials. PMID 42342498 — urinary bladder, urinary bladder neoplasms, muscles, neoplasms, urologic neoplasms, cystectomy, therapeutics, surrogacy | Eur Urol Oncol | 2026 | 3 |
| Endoscopic kidney-sparing surgery for upper tract urothelial carcinoma in patients with a solitary kidney. PMID 42749682 — mortality, incidence, neoplasms, ureteroscopy, kidney, solitary kidney, nephroureterectomy, dependency, psychological | BJU Int | 2026 | 0 |
| Surrogacy of intermediate clinical endpoints for overall survival in BCG-naïve high-risk non-muscle-invasive bladder cancer. PMID 42823574 — urinary bladder, urinary bladder neoplasms, disease-free survival, muscles, neoplasms, therapeutics, non-muscle invasive bladder neoplasms, surrogacy | World J Urol | 2026 | 0 |
| Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy. PMID 42632232 — urinary bladder, urinary bladder neoplasms, muscles, probability, neoplasms, immunotherapy, immune checkpoint inhibitors, prostatic neoplasms, neoadjuvant therapy, kidney neoplasms, precision medicine, therapeutics | Clin Genitourin Cancer | 2026 | 0 |
| Immunohistochemical stratification of bladder small cell carcinoma reveals two major phenotypes with distinct therapeutic biomarker profiles. PMID 42747234 — urinary bladder, urinary bladder neoplasms, cells, pathology, phenotype, carcinoma, small cell, biomarkers, histology, therapeutics | Histopathology | 2026 | 0 |
Clinical Studies 8
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Predictive Role of Microbiome in Patients With Urothelial Carcinoma NCT06675656 — cytokines, urinary bladder, carcinoma, transitional cell, urinary bladder neoplasms, cells, blood, serum, neoplasms, biopsy, dna, non-muscle invasive bladder neoplasms, carcinoma | N/A | Not yet recruiting | 2024 |
| Pre operative Immuno Nutrition in Radical Cystectomy NCT06355518 — urinary bladder, urinary bladder neoplasms, fatty acids, omega-3, arginine, neoplasms, cystectomy, therapeutics, rna, fatty acids | N/A | Not yet recruiting | 2024 |
| Multicentric Prospective T1 Urinary Bladder Cancer Registry NCT05792033 — registries, urinary bladder, urinary bladder neoplasms, pathologists, neoplasms, pathology, privacy, cystectomy, diagnosis, therapeutics, prognosis | N/A | Recruiting | 2021 |
| Pembrolizumab Sacituzumab Govitecan Combination to Treat High risk Localized Bladder Cancer NCT05535218 — urinary bladder, urinary bladder neoplasms, muscles, neoplasms, drug therapy, neoadjuvant therapy, accounting, therapeutics, chemotherapy | Phase 2 | Active not recruiting | 2023 |
| An Open Label Single arm Phase 2 Study of Neoadjuvant Nivolumab and Nab paclitaxel Before Radical Cystectomy for Patients With Muscle invasive Bladder Cancer (NURE Combo) NCT04876313 — urinary bladder, urinary bladder neoplasms, muscles, paclitaxel, neoplasms, cystectomy, nivolumab, carcinoma | Phase 2 | Recruiting | 2022 |
LeadR Networks
Main global connection map